Prestige Wealth Management Group LLC Outlook Therapeutics, Inc. Transaction History

Prestige Wealth Management Group LLC

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 Apr 26, 2024	BUY	$1.0 - $1.35 $1,250 - $1,687	1,250 New	1,250 $1,000
Q3 2019 Nov 14, 2019	BUY	$1.32 - $2.63 $1,650 - $3,287	1,250 New	1,250 $2,000
Q2 2019 Aug 16, 2019	SELL	$0.91 - $7.68 $1,137 - $9,600	-1,250 Closed	0 $0
Q1 2019 Aug 16, 2019	BUY	$4.26 - $10.56 $5,325 - $13,200	1,250 New	1,250 $9,000

67.1K

Ticker OTLK
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 226,144,992
Market Cap $1.66B
Description
Outlook Therapeutics, Inc., a late clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-relate...

Get notified when there are updates to the investment portfolio of Prestige Wealth Management Group LLC, based on Form 13F filings with the SEC.

Stay updated on Prestige Wealth Management Group LLC with notifications on news.